Analysis Of Influencing Factors On The Efficacy Of Diffuse Large B - Cell Lymphoma In Germinal Center And Non - Germinal Center

Objective To evaluate the clinical outcome、effective factors and side-effects of CHOP chemotherapy plus rituximab in treating diffuse large B cell lymphoma(DLBCL).Method We retrospectively analyzed 74 newly diagnosed patients with DLBCL who treated in our hospital from January 2008 to October 2014.41 cases were treated with R-CHOP(R-CHOP group)and 33 cases were treated with CHOP(CHOP group); There were 13 GCB types(GCB type in R-CHOP group)and 28 non-GCB types(non-GCB type in R-CHOP group) in the R-CHOP group,While the CHOP group was divided into 11 GCB types(GCB type in CHOP group) and 22 non-GCB types(non-GCB type in CHOP group).To compare their RR、 1-year survival rate and the effective factors.And to analyzed the side-effects in R-CHOP and CHOP.Results The rate of RR and 1-year survival rate in R-CHOP group were higher than that in CHOP type(P<0.05); The rate of RR and 1-year survival rate in GCB type were higher than that in non-GCB type(P<0.05); The GCB type’s rate of RR was higher than non-GCB type in CHOP group(P<0.01),but they had no statistical difference in1-year surival rate(P>0.05). GCB type in R-CHOP group’s 1-year-survival rate stayed ahead of CHOP group in GCB tpye in CHOP group(P<0.05),but no statistical difference was found in the rate of RR between the two groups(P>0.05).Non-GCB type in R-CHOP group ’s RR rate was higher than non-GCB type in CHOP group(P<0.05),but there’s no statistical difference in 1-year surival rate between them(P>0.05).At the same time we found that the positive of Ki-67,LDH levels,clinical stage and IPI scores affect the rate of RR by analysed the signal factors(P<0.05),expecially in non-GCB type.Age、sex、B symptom and ALC had no connection with RR.Conclusion ①The effect and 1-year surival of R-CHOP group is better than CHOP group,and there has no significant diffetence in the side-effects.②The GCB type had better RR rate and 1-year surival than non-GCB type;R-CHOP can improve the RR rate in non-GCB type and the 1-year-surival.③The positive of Ki-67,LDH levels,clinical stage and IPI scores affect the therapeutic effect of DLBCL,especially in non-GCB type.④ALC<1*10~9/L has connection with clinical stage and IPI scores.